Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook

Table of Contents

July 15, 2022; Volume 19,Issue 7
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

C

  1. Chang, Yu

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  2. Chen, Jinghong

    1. You have access
      Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598
  3. Chen, Kexin

    1. You have access
      Living biobank-based cancer organoids: prospects and challenges in cancer research
      Haixin Li, Hongkun Liu and Kexin Chen
      Cancer Biology & Medicine July 2022, 19 (7) 965-982; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0621
  4. Chen, Sheng

    1. You have access
      Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085
  5. Chen, Xin

    1. You have access
      Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598
  6. Chen, Yongzi

    1. You have access
      Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516
  7. Cheng, Jingyi

    1. You have access
      Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085
  8. Cheng, Kai

    1. You have access
      IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583
  9. Cheng, Runfen

    1. You have access
      Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516
  10. Cheng, Zhigang

    1. You have access
      Microwave ablation vs. surgical resection for treatment naïve hepatocellular carcinoma within the Milan criteria: a follow-up of at least 5 years
      Jianping Dou, Zhigang Cheng, Zhiyu Han, Fangyi Liu, Zhen Wang, Xiaoling Yu, Jie Yu and Ping Liang
      Cancer Biology & Medicine July 2022, 19 (7) 1078-1088; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0625
  11. Cui, Daxiang

    1. You have access
      Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages
      Yu Han, Yuming Yang, Qiuyang Sun, Bin Li, Caixia Yue, Yanlei Liu, Jesús M. de la Fuente and Daxiang Cui
      Cancer Biology & Medicine July 2022, 19 (7) 1047-1060; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0416

D

  1. de la Fuente, Jesús M.

    1. You have access
      Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages
      Yu Han, Yuming Yang, Qiuyang Sun, Bin Li, Caixia Yue, Yanlei Liu, Jesús M. de la Fuente and Daxiang Cui
      Cancer Biology & Medicine July 2022, 19 (7) 1047-1060; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0416
  2. Di, Genghong

    1. You have access
      Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085
  3. Ding, Mengjie

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  4. Dong, Meng

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  5. Dou, Jianping

    1. You have access
      Microwave ablation vs. surgical resection for treatment naïve hepatocellular carcinoma within the Milan criteria: a follow-up of at least 5 years
      Jianping Dou, Zhigang Cheng, Zhiyu Han, Fangyi Liu, Zhen Wang, Xiaoling Yu, Jie Yu and Ping Liang
      Cancer Biology & Medicine July 2022, 19 (7) 1078-1088; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0625
  6. Dou, Q. Ping

    1. You have access
      Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598
  7. Du, Liqing

    1. You have access
      ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
      Yi Xie, Bing Wang, Liqing Du, Yan Wang, Chang Xu, Hong Zhang, Kaixue Wen, Qiang Liu and Takanori Katsube
      Cancer Biology & Medicine July 2022, 19 (7) 983-994; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0569

F

  1. Feng, Tingting

    1. You have access
      IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583
  2. Fu, Xiaorui

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

G

  1. Gao, Fenghua

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  2. Ge, Luna

    1. You have access
      IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583

H

  1. Han, Yu

    1. You have access
      Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages
      Yu Han, Yuming Yang, Qiuyang Sun, Bin Li, Caixia Yue, Yanlei Liu, Jesús M. de la Fuente and Daxiang Cui
      Cancer Biology & Medicine July 2022, 19 (7) 1047-1060; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0416
  2. Han, Zhiyu

    1. You have access
      Microwave ablation vs. surgical resection for treatment naïve hepatocellular carcinoma within the Milan criteria: a follow-up of at least 5 years
      Jianping Dou, Zhigang Cheng, Zhiyu Han, Fangyi Liu, Zhen Wang, Xiaoling Yu, Jie Yu and Ping Liang
      Cancer Biology & Medicine July 2022, 19 (7) 1078-1088; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0625
  3. Hao, Yali

    1. You have access
      Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598
  4. Hou, Yifeng

    1. You have access
      Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085
  5. Huang, Liang

    1. You have access
      Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085
  6. Huang, Qingtian

    1. You have access
      Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598

J

  1. Jiang, Wenna

    1. You have access
      Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516
  2. Jiang, Yizhou

    1. You have access
      Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085

K

  1. Katsube, Takanori

    1. You have access
      ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
      Yi Xie, Bing Wang, Liqing Du, Yan Wang, Chang Xu, Hong Zhang, Kaixue Wen, Qiang Liu and Takanori Katsube
      Cancer Biology & Medicine July 2022, 19 (7) 983-994; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0569

L

  1. Lei, Ziying

    1. You have access
      Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598
  2. Li, Bin

    1. You have access
      Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages
      Yu Han, Yuming Yang, Qiuyang Sun, Bin Li, Caixia Yue, Yanlei Liu, Jesús M. de la Fuente and Daxiang Cui
      Cancer Biology & Medicine July 2022, 19 (7) 1047-1060; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0416
  3. Li, Binghui

    1. You have access
      SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation
      Liao Wang, Yinghui Sun, Xijie Liu, Hongjuan Li, Chang Lu, Ronghui Yang, Chuanzhen Yang and Binghui Li
      Cancer Biology & Medicine July 2022, 19 (7) 995-1007; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0291
  4. Li, Haixin

    1. You have access
      Living biobank-based cancer organoids: prospects and challenges in cancer research
      Haixin Li, Hongkun Liu and Kexin Chen
      Cancer Biology & Medicine July 2022, 19 (7) 965-982; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0621
  5. Li, Hongjuan

    1. You have access
      SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation
      Liao Wang, Yinghui Sun, Xijie Liu, Hongjuan Li, Chang Lu, Ronghui Yang, Chuanzhen Yang and Binghui Li
      Cancer Biology & Medicine July 2022, 19 (7) 995-1007; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0291
  6. Li, Junjie

    1. You have access
      Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085
  7. Li, Ling

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  8. Li, Xiaofen

    1. You have access
      Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598
  9. Li, Xin

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  10. Li, Yangling

    1. You have access
      Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
      Yangling Li, Dongmei Zhou, Shuang Xu, Mingjun Rao, Zuoyan Zhang, Linwen Wu, Chong Zhang and Nengming Lin
      Cancer Biology & Medicine July 2022, 19 (7) 1109-1110; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0172
  11. Li, Zhaoming

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  12. Liang, Ping

    1. You have access
      Microwave ablation vs. surgical resection for treatment naïve hepatocellular carcinoma within the Milan criteria: a follow-up of at least 5 years
      Jianping Dou, Zhigang Cheng, Zhiyu Han, Fangyi Liu, Zhen Wang, Xiaoling Yu, Jie Yu and Ping Liang
      Cancer Biology & Medicine July 2022, 19 (7) 1078-1088; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0625
  13. Lin, Nengming

    1. You have access
      Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
      Yangling Li, Dongmei Zhou, Shuang Xu, Mingjun Rao, Zuoyan Zhang, Linwen Wu, Chong Zhang and Nengming Lin
      Cancer Biology & Medicine July 2022, 19 (7) 1109-1110; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0172
  14. Liu, Fangyi

    1. You have access
      Microwave ablation vs. surgical resection for treatment naïve hepatocellular carcinoma within the Milan criteria: a follow-up of at least 5 years
      Jianping Dou, Zhigang Cheng, Zhiyu Han, Fangyi Liu, Zhen Wang, Xiaoling Yu, Jie Yu and Ping Liang
      Cancer Biology & Medicine July 2022, 19 (7) 1078-1088; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0625
  15. Liu, Guangyu

    1. You have access
      Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085
  16. Liu, Hongkun

    1. You have access
      Living biobank-based cancer organoids: prospects and challenges in cancer research
      Haixin Li, Hongkun Liu and Kexin Chen
      Cancer Biology & Medicine July 2022, 19 (7) 965-982; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0621
  17. Liu, Jinbao

    1. You have access
      Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598
  18. Liu, Qiang

    1. You have access
      ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
      Yi Xie, Bing Wang, Liqing Du, Yan Wang, Chang Xu, Hong Zhang, Kaixue Wen, Qiang Liu and Takanori Katsube
      Cancer Biology & Medicine July 2022, 19 (7) 983-994; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0569
  19. Liu, Rui

    1. You have access
      Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516
  20. Liu, Xijie

    1. You have access
      SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation
      Liao Wang, Yinghui Sun, Xijie Liu, Hongjuan Li, Chang Lu, Ronghui Yang, Chuanzhen Yang and Binghui Li
      Cancer Biology & Medicine July 2022, 19 (7) 995-1007; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0291
  21. Liu, Yanlei

    1. You have access
      Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages
      Yu Han, Yuming Yang, Qiuyang Sun, Bin Li, Caixia Yue, Yanlei Liu, Jesús M. de la Fuente and Daxiang Cui
      Cancer Biology & Medicine July 2022, 19 (7) 1047-1060; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0416
  22. Lu, Chang

    1. You have access
      SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation
      Liao Wang, Yinghui Sun, Xijie Liu, Hongjuan Li, Chang Lu, Ronghui Yang, Chuanzhen Yang and Binghui Li
      Cancer Biology & Medicine July 2022, 19 (7) 995-1007; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0291
  23. Lu, Qiqi

    1. You have access
      IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583

N

  1. Nan, Feifei

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  2. Niu, Songtao

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

P

  1. Pan, Jihong

    1. You have access
      IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583

Q

  1. Qu, Feilin

    1. You have access
      Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085

R

  1. Rao, Mingjun

    1. You have access
      Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
      Yangling Li, Dongmei Zhou, Shuang Xu, Mingjun Rao, Zuoyan Zhang, Linwen Wu, Chong Zhang and Nengming Lin
      Cancer Biology & Medicine July 2022, 19 (7) 1109-1110; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0172
  2. Ren, Li

    1. You have access
      Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516

S

  1. Shao, Zhimin

    1. You have access
      Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085
  2. Song, Guanhua

    1. You have access
      IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583
  3. Sun, Lu

    1. You have access
      Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516
  4. Sun, Qiuyang

    1. You have access
      Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages
      Yu Han, Yuming Yang, Qiuyang Sun, Bin Li, Caixia Yue, Yanlei Liu, Jesús M. de la Fuente and Daxiang Cui
      Cancer Biology & Medicine July 2022, 19 (7) 1047-1060; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0416
  5. Sun, Yi

    1. You have access
      Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516
  6. Sun, Yinghui

    1. You have access
      SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation
      Liao Wang, Yinghui Sun, Xijie Liu, Hongjuan Li, Chang Lu, Ronghui Yang, Chuanzhen Yang and Binghui Li
      Cancer Biology & Medicine July 2022, 19 (7) 995-1007; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0291
  7. Sun, Zhenchang

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  8. Sun, Zhijun

    1. You have access
      Eliciting pyroptosis to fuel cancer immunotherapy: mechanisms and strategies
      Wuyin Wang, Lu Zhang and Zhijun Sun
      Cancer Biology & Medicine July 2022, 19 (7) 948-964; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0049

T

  1. Tang, Bo

    1. You have access
      Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF
      Hongquan Wang, Shuang Wu, Yan Wang and Bo Tang
      Cancer Biology & Medicine July 2022, 19 (7) 945-947; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0299
  2. Tang, Daolin

    1. You have access
      Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598
  3. Tang, Fan

    1. You have access
      Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516

W

  1. Wang, Bing

    1. You have access
      ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
      Yi Xie, Bing Wang, Liqing Du, Yan Wang, Chang Xu, Hong Zhang, Kaixue Wen, Qiang Liu and Takanori Katsube
      Cancer Biology & Medicine July 2022, 19 (7) 983-994; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0569
  2. Wang, Hongquan

    1. You have access
      Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF
      Hongquan Wang, Shuang Wu, Yan Wang and Bo Tang
      Cancer Biology & Medicine July 2022, 19 (7) 945-947; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0299
  3. Wang, Jing

    1. You have access
      IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583
  4. Wang, Liao

    1. You have access
      SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation
      Liao Wang, Yinghui Sun, Xijie Liu, Hongjuan Li, Chang Lu, Ronghui Yang, Chuanzhen Yang and Binghui Li
      Cancer Biology & Medicine July 2022, 19 (7) 995-1007; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0291
  5. Wang, Lin

    1. You have access
      IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583
  6. Wang, Shiguan

    1. You have access
      IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583
  7. Wang, Wenhua

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  8. Wang, Wuyin

    1. You have access
      Eliciting pyroptosis to fuel cancer immunotherapy: mechanisms and strategies
      Wuyin Wang, Lu Zhang and Zhijun Sun
      Cancer Biology & Medicine July 2022, 19 (7) 948-964; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0049
  9. Wang, Xinhua

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  10. Wang, Yan

    1. You have access
      Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF
      Hongquan Wang, Shuang Wu, Yan Wang and Bo Tang
      Cancer Biology & Medicine July 2022, 19 (7) 945-947; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0299
    2. You have access
      Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085
    3. You have access
      ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
      Yi Xie, Bing Wang, Liqing Du, Yan Wang, Chang Xu, Hong Zhang, Kaixue Wen, Qiang Liu and Takanori Katsube
      Cancer Biology & Medicine July 2022, 19 (7) 983-994; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0569
  11. Wang, Zhen

    1. You have access
      Microwave ablation vs. surgical resection for treatment naïve hepatocellular carcinoma within the Milan criteria: a follow-up of at least 5 years
      Jianping Dou, Zhigang Cheng, Zhiyu Han, Fangyi Liu, Zhen Wang, Xiaoling Yu, Jie Yu and Ping Liang
      Cancer Biology & Medicine July 2022, 19 (7) 1078-1088; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0625
  12. Wang, Zhuozhi

    1. You have access
      Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516
  13. Wen, Kaixue

    1. You have access
      ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
      Yi Xie, Bing Wang, Liqing Du, Yan Wang, Chang Xu, Hong Zhang, Kaixue Wen, Qiang Liu and Takanori Katsube
      Cancer Biology & Medicine July 2022, 19 (7) 983-994; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0569
  14. Wu, Jingjing

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  15. Wu, Linwen

    1. You have access
      Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
      Yangling Li, Dongmei Zhou, Shuang Xu, Mingjun Rao, Zuoyan Zhang, Linwen Wu, Chong Zhang and Nengming Lin
      Cancer Biology & Medicine July 2022, 19 (7) 1109-1110; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0172
  16. Wu, Shuang

    1. You have access
      Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF
      Hongquan Wang, Shuang Wu, Yan Wang and Bo Tang
      Cancer Biology & Medicine July 2022, 19 (7) 945-947; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0299
  17. Wu, Xiaolong

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026

X

  1. Xie, Yi

    1. You have access
      ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
      Yi Xie, Bing Wang, Liqing Du, Yan Wang, Chang Xu, Hong Zhang, Kaixue Wen, Qiang Liu and Takanori Katsube
      Cancer Biology & Medicine July 2022, 19 (7) 983-994; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0569
  2. Xu, Chang

    1. You have access
      ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
      Yi Xie, Bing Wang, Liqing Du, Yan Wang, Chang Xu, Hong Zhang, Kaixue Wen, Qiang Liu and Takanori Katsube
      Cancer Biology & Medicine July 2022, 19 (7) 983-994; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0569
  3. Xu, Shuang

    1. You have access
      Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
      Yangling Li, Dongmei Zhou, Shuang Xu, Mingjun Rao, Zuoyan Zhang, Linwen Wu, Chong Zhang and Nengming Lin
      Cancer Biology & Medicine July 2022, 19 (7) 1109-1110; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0172
  4. Xue, Qian

    1. You have access
      Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598

Y

  1. Yan, Ding

    1. You have access
      Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598
  2. Yan, Jiaqian

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  3. Yang, Benglong

    1. You have access
      Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085
  4. Yang, Chuanzhen

    1. You have access
      SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation
      Liao Wang, Yinghui Sun, Xijie Liu, Hongjuan Li, Chang Lu, Ronghui Yang, Chuanzhen Yang and Binghui Li
      Cancer Biology & Medicine July 2022, 19 (7) 995-1007; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0291
  5. Yang, Ronghui

    1. You have access
      SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation
      Liao Wang, Yinghui Sun, Xijie Liu, Hongjuan Li, Chang Lu, Ronghui Yang, Chuanzhen Yang and Binghui Li
      Cancer Biology & Medicine July 2022, 19 (7) 995-1007; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0291
  6. Yang, Yuming

    1. You have access
      Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages
      Yu Han, Yuming Yang, Qiuyang Sun, Bin Li, Caixia Yue, Yanlei Liu, Jesús M. de la Fuente and Daxiang Cui
      Cancer Biology & Medicine July 2022, 19 (7) 1047-1060; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0416
  7. Yao, Leyi

    1. You have access
      Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598
  8. Yu, Hui

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  9. Yu, Jie

    1. You have access
      Microwave ablation vs. surgical resection for treatment naïve hepatocellular carcinoma within the Milan criteria: a follow-up of at least 5 years
      Jianping Dou, Zhigang Cheng, Zhiyu Han, Fangyi Liu, Zhen Wang, Xiaoling Yu, Jie Yu and Ping Liang
      Cancer Biology & Medicine July 2022, 19 (7) 1078-1088; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0625
  10. Yu, Keda

    1. You have access
      Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
      Junjie Li, Jingyi Cheng, Guangyu Liu, Yifeng Hou, Genghong Di, Benglong Yang, Yizhou Jiang, Liang Huang, Feilin Qu, Sheng Chen, Yan Wang, Keda Yu and Zhimin Shao
      Cancer Biology & Medicine July 2022, 19 (7) 1100-1108; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0085
  11. Yu, Xiaoling

    1. You have access
      Microwave ablation vs. surgical resection for treatment naïve hepatocellular carcinoma within the Milan criteria: a follow-up of at least 5 years
      Jianping Dou, Zhigang Cheng, Zhiyu Han, Fangyi Liu, Zhen Wang, Xiaoling Yu, Jie Yu and Ping Liang
      Cancer Biology & Medicine July 2022, 19 (7) 1078-1088; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0625
  12. Yue, Caixia

    1. You have access
      Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages
      Yu Han, Yuming Yang, Qiuyang Sun, Bin Li, Caixia Yue, Yanlei Liu, Jesús M. de la Fuente and Daxiang Cui
      Cancer Biology & Medicine July 2022, 19 (7) 1047-1060; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0416

Z

  1. Zhang, Chong

    1. You have access
      Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
      Yangling Li, Dongmei Zhou, Shuang Xu, Mingjun Rao, Zuoyan Zhang, Linwen Wu, Chong Zhang and Nengming Lin
      Cancer Biology & Medicine July 2022, 19 (7) 1109-1110; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0172
  2. Zhang, Hong

    1. You have access
      ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
      Yi Xie, Bing Wang, Liqing Du, Yan Wang, Chang Xu, Hong Zhang, Kaixue Wen, Qiang Liu and Takanori Katsube
      Cancer Biology & Medicine July 2022, 19 (7) 983-994; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0569
  3. Zhang, Jieming

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  4. Zhang, Lei

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  5. Zhang, Lu

    1. You have access
      Eliciting pyroptosis to fuel cancer immunotherapy: mechanisms and strategies
      Wuyin Wang, Lu Zhang and Zhijun Sun
      Cancer Biology & Medicine July 2022, 19 (7) 948-964; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0049
  6. Zhang, Mingzhi

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  7. Zhang, Qingyun

    1. You have access
      IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583
  8. Zhang, Xinwei

    1. You have access
      Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516
  9. Zhang, Xudong

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  10. Zhang, Zuoyan

    1. You have access
      Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
      Yangling Li, Dongmei Zhou, Shuang Xu, Mingjun Rao, Zuoyan Zhang, Linwen Wu, Chong Zhang and Nengming Lin
      Cancer Biology & Medicine July 2022, 19 (7) 1109-1110; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0172
  11. Zhao, Qian

    1. You have access
      Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
      Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen and Jinbao Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1061-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0598
  12. Zhao, Ru

    1. You have access
      IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
      Tingting Feng, Jing Wang, Kai Cheng, Qiqi Lu, Ru Zhao, Shiguan Wang, Qingyun Zhang, Luna Ge, Jihong Pan, Guanhua Song and Lin Wang
      Cancer Biology & Medicine July 2022, 19 (7) 1008-1028; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0583
  13. Zhou, Dongmei

    1. You have access
      Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
      Yangling Li, Dongmei Zhou, Shuang Xu, Mingjun Rao, Zuoyan Zhang, Linwen Wu, Chong Zhang and Nengming Lin
      Cancer Biology & Medicine July 2022, 19 (7) 1109-1110; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0172
  14. Zhou, Zhiyuan

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  15. Zhu, Linan

    1. You have access
      Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
      Jingjing Wu, Fenghua Gao, Wenhua Wang, Xudong Zhang, Meng Dong, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Linan Zhu, Mengjie Ding, Songtao Niu, Zhaoming Li, Yu Chang, Feifei Nan, Jiaqian Yan, Hui Yu, Xiaolong Wu, Zhiyuan Zhou, Jieming Zhang and Mingzhi Zhang
      Cancer Biology & Medicine July 2022, 19 (7) 1089-1099; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0026
  16. Zuo, Duo

    1. You have access
      Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
      Duo Zuo, Yongzi Chen, Xinwei Zhang, Zhuozhi Wang, Wenna Jiang, Fan Tang, Runfen Cheng, Yi Sun, Lu Sun, Li Ren and Rui Liu
      Cancer Biology & Medicine July 2022, 19 (7) 1029-1046; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0516
Back to top
PreviousNext

In this issue

Cancer Biology & Medicine: 19 (7)
Cancer Biology & Medicine
Vol. 19, Issue 7
15 Jul 2022
  • Table of Contents
  • Index by author

Submit

Sign up for alerts

  • Top Topics
  • Most Cited
  • Most Read
Loading
The advanced development of molecular targeted therapy for hepatocellular carcinoma
The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma
Immunology and immunotherapy in breast cancer
Effects of menopausal hormone therapy-based on the role of estrogens, progestogens, and their metabolites in proliferation of breast cancer cells
Breast cancer screening and early diagnosis in Chinese women
Is adjuvant chemotherapy necessary for early gastric cancer?
Modulating microRNAs in cancer: next-generation therapies
Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma
Personalized immunotherapy in cancer precision medicine
Cellular immunotherapy for hematological malignancy: recent progress and future perspectives

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2022 Cancer Biology & Medicine

Powered by HighWire